Loading...
Loading...
INNOCAN PHARMA Corp
INNOCAN PHARMA Corp. Spoken Alpha tracks INNPF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks INNPF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 8/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for INNPF.
curl https://api.spokenalpha.com/v1/companies/INNPF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.90 | $0.93 | -2.9% | +2.1% | +4.4% |
| Q4 FY2026 | $1.00 | $1.10 | -9.5% | -2.5% | -2.4% |
| Q3 FY2026 | $1.05 | $1.04 | +1.2% | -0.8% | -0.3% |
| Q2 FY2026 | $1.02 | $1.06 | -3.8% | +0.9% | -0.3% |
| Q1 FY2025 | $1.04 | $1.12 | -6.9% | -3.4% | -2.4% |
| Q4 FY2025 | $1.11 | $1.18 | -6.2% | +3.0% | +4.5% |
| Q3 FY2025 | $1.03 | $1.03 | -0.2% | +2.9% | +2.1% |
| Q2 FY2025 | $0.93 | $1.00 | -6.9% | -3.7% | -2.3% |
| Q1 FY2024 | $1.06 | $1.12 | -5.2% | +0.1% | +2.0% |
| Q4 FY2024 | $1.16 | $1.19 | -2.5% | -5.5% | -3.7% |